Lisa Kinget

MD, PhD, medical oncology resident @uzleuven @KU_Leuven - passionate about biomarkers in clear-cell renal cell carcinoma 🇧🇪

[Lisa Kinget @LisaKinget]

Finally, thanks to all my colleagues, family and friends who helped and supported me along the way.
After this amazing journey at @KU_Leuven @Onco_KULeuven, excited for my final 2 years of medical oncology training at @UZLeuven!

[Lisa Kinget @LisaKinget]

#PhDone! 👩‍🎓
Last week, I successfully defended my PhD on response prediction for systemic therapies in clear-cell RCC.
Incredibly grateful for the support of my supervisors professors Benoit Beuselinck, @AbhishekDGarg and @MaartenAlbersen!

[Lisa Kinget @LisaKinget]

Thanks as well to my jury members professors Els Wauters @ewauters, Jeroen Dekervel @JDekervel, Yann Vano and Henrik Heiland @MILOLab2, for their constructive feedback and insightful questions!

[Cell Stress & Immunity (CSI) @AbhishekDGarg]

📢Thrilled to share our lab's latest research on unique, #evolutionarily #conserved, TIM3+VISTA+ #macrophage subset that mediates #resistance to #anticancer #Immunotherapy & #chemotherapy! @ScienceAdvances 1/11🧵
📑Read here:
https://t.co/GG5pYNCP5q
@OncoAlert @oncodaily @OncLive

[Belgian Society of Medical Oncology @mybsmo]

Read this excellent work by one of our young BSMO members @LisaKinget in @NatureMedicine
"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma" @KidneyCancer @UZLeuven @mybsmo @AbhishekDGarg https://t.co/QTFhRA8q3p

[Cell Stress & Immunity (CSI) @AbhishekDGarg]

🚨Read @CD_AACR #ResearchWatch snippet on our recent work!
"A Multiomics-Informed HLA Signature Predicts Immunotherapy Response"
🗞️Read full paper here: https://t.co/allKa3xTvE

[Enrique Grande @drenriquegrande]

⚡️ On @NatureMedicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

#KidneyCancer #Immunotherapy @OncoAlert @OncLive

https://t.co/oMxxqaQRlF

[Cell Stress & Immunity (CSI) @AbhishekDGarg]

🙏Thanks @CD_AACR for highlighting our recent research on #kidneycancer #immunotherapy & #immunology and #artificialintelligence driven #biomarkers!

@KU_Leuven @UZLeuven @KidneyCancer @LisaKinget
https://t.co/3UjjOyqW8n

[Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber_GU]

GU Research Digest for the week of May 18 - 25: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on https://t.co/F03S8cX7Rn to read!

[OncoDaily @oncodaily]

Cell Stress and Immunity Lab - Heritable and spatial immunogenic traits predict efficacy of immunotherapy responses in kidney cancer patients
@AbhishekDGarg @NatureMedicine @LisaKinget @snaulrts @Zucmanrossi @MaartenAlbersen
https://t.co/ID1byy1nHY

#Cancer #OncoDaily #Oncology

[OncoDaily @oncodaily]

Thrilled to share our lab's latest research on multiomics and spatial mapping of immunotherapy responses in kidney cancer patients - @AbhishekDGarg
@KU_Leuven @FWOVlaanderen @med_fac @UZLeuven @LKILeuven @komop_tgkanker
https://t.co/TrIDqvttG9

#Cancer #OncoDaily #Oncology

[Dimitris Lagos @DimitrisLagos04]

This paper by @AbhishekDGarg and colleagues addresses some key questions in ccRCC, including some key features of responders to immunotherapy. Extremely useful read. Congratulations to all involved, wonderful work!
https://t.co/cGJXHG38NK

[Lisa Kinget @LisaKinget]

@TurajlicLab @AbhishekDGarg Thank you!

[Mate Manczinger @matemanc]

It is great to see the significant effect of HLA promiscuity in the ICB treatment of renal cancer. Congratulations to the authors, great study!

https://t.co/9ShfEEaJFq

#cancer #immunotherapy #hla #tumor #kidney #kidneycancer

@LisaKinget @Francesca_Fin_ @AbhishekDGarg

[OncoAlert @OncoAlert]

The OncoAlert🚨NEWSLETTER OUT
Covering May 17-23 , 2024

REGISTER at https://t.co/QFM2SYXY0O OR https://t.co/hwvqbilJBm

Discussing:
✅ICI’s 💉for POLE or POLD1 in met CRC
✅Advancements in mgt of Synchronous CRC Liver Mets
✅5yr outcome w/pembro💉 mono NSCLC🫁
✅SBRT☢️ in Lung Cancer🫁
✅RIGHT Choice in #BreastCancer 💊
✅Selection of Germline Genetic Testing Panels in Patients With Cancer: @ASCO Guidelines
✅A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
✅Incidence of SLN mets in early #EndometrialCancer
✅Characterization of HER2-low 🧬breast cancer in young women with germline #BRCA 1/2 pathogenetic variants

@pashtoonkasi @margheambro1 @FilippoPietran4
@Mom_enji @Areeb_Lutfi @cihangirakyol
@Eda_Eylmr_Mcn @StephenVLiu @VamsiVelcheti
@HenningWillers @PercyLeeMD @Icro_Meattini @katsuki_arima @StoverLab @FrancescoSche20 @umangtalking @SGreenbergGC @vinay_onc
@neerajaiims @Lucarecco @LisaKinget
@drenriquegrande @IJGCfellows @JayrajAarthi
@IJGConline @matteolambe @BenWestphalen @DrYukselUrun @PGrivasMDPhD

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth @anmwongNZ

[Yüksel Ürün @DrYukselUrun]

Spatial HLA signature may predicts response to immunotherapy in advanced renal cell carcinoma.
@NatureMedicine @OncoAlert #CancerResearch #oncology #kidney
https://t.co/eObNa7pCOu

[Enrique Grande @drenriquegrande]

⚡️ On @NatureMedicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

#KidneyCancer #Immunotherapy @OncoAlert @OncLive

https://t.co/4YCtwQSA5S

[Nature Medicine @NatureMedicine]

Multiomics & spatial mapping of tumor samples from patients with advanced #RenalCellCarcinoma, as well as integration of transcriptomic and HLA genotyping data provides a machine learning-derived signature of response to #immune #CheckpointBlockade.
https://t.co/7a9LuV2txp

[Eduard Roussel @Eduardrssl]

Incredible work unravelling key features of ICB responsiveness in RCC spearheaded by @LisaKinget @KU_Leuven, out now in @NatureMedicine!

[Cell Stress & Immunity (CSI) @AbhishekDGarg]

https://t.co/sbjrSk0FEt